ATE483459T1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents

Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Info

Publication number
ATE483459T1
ATE483459T1 AT00941235T AT00941235T ATE483459T1 AT E483459 T1 ATE483459 T1 AT E483459T1 AT 00941235 T AT00941235 T AT 00941235T AT 00941235 T AT00941235 T AT 00941235T AT E483459 T1 ATE483459 T1 AT E483459T1
Authority
AT
Austria
Prior art keywords
oxybutynin
smooth muscle
desethyloxybutynin
treating
optically pure
Prior art date
Application number
AT00941235T
Other languages
German (de)
English (en)
Inventor
A Aberg
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483459T1 publication Critical patent/ATE483459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00941235T 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin ATE483459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/015515 WO2001093683A1 (en) 2000-06-07 2000-06-07 Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin

Publications (1)

Publication Number Publication Date
ATE483459T1 true ATE483459T1 (de) 2010-10-15

Family

ID=21741461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941235T ATE483459T1 (de) 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Country Status (9)

Country Link
EP (1) EP1286591B1 (enExample)
JP (1) JP5684964B2 (enExample)
CN (3) CN101108176A (enExample)
AT (1) ATE483459T1 (enExample)
AU (2) AU5596600A (enExample)
CA (1) CA2378754A1 (enExample)
DE (1) DE60045082D1 (enExample)
ES (1) ES2350330T3 (enExample)
WO (1) WO2001093683A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002241721A1 (en) * 2001-12-21 2003-09-02 Bridge Pharma, Inc. A non-arrhythmogenic metabolite of oxybutynin
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PT1629850E (pt) * 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US9370528B2 (en) 2011-03-02 2016-06-21 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
WO2012167212A2 (en) 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
CN103169660B (zh) * 2013-04-15 2015-04-08 石正国 一种制备高包封率的利巴韦林脂质体口服乳
WO2015095576A1 (en) * 2013-12-18 2015-06-25 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP3207931A3 (en) 2014-06-03 2017-12-20 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
KR102638618B1 (ko) 2016-04-27 2024-02-21 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
CR20220617A (es) * 2020-05-05 2023-02-09 Apnimed Inc Formas polimórficas de clorhidrato de (r)-oxibutinina
AU2021298896A1 (en) * 2020-07-03 2023-02-16 Phoxbio Limited Reduction of viral infections
CN117396460A (zh) * 2021-05-04 2024-01-12 爱普宁公司(特拉华) (r)-奥昔布宁d-苹果酸盐的固体形式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008269A (en) * 1970-05-05 1977-02-15 William H. Rorer, Inc. Phenylacetic acids
IT1231237B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati eterociclici
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters

Also Published As

Publication number Publication date
CA2378754A1 (en) 2001-12-13
AU2000255966B2 (en) 2005-03-24
ES2350330T3 (es) 2011-01-21
AU2000255966A1 (en) 2002-03-07
EP1286591A4 (en) 2007-04-04
AU5596600A (en) 2001-12-17
EP1286591B1 (en) 2010-10-06
JP5684964B2 (ja) 2015-03-18
CN1454054A (zh) 2003-11-05
CN101108176A (zh) 2008-01-23
DE60045082D1 (de) 2010-11-18
EP1286591A1 (en) 2003-03-05
CN1451388A (zh) 2003-10-29
WO2001093683A1 (en) 2001-12-13
JP2003535110A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
DE60045082D1 (de) Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin
CA2451474A1 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
CY1108808T1 (el) Ενωσεις μοτιλιδης
AU2001283963A1 (en) Polysiloxane polymers, method for their production and the use thereof
AU2001249091A1 (en) Novel methods using cholinesterase inhibitors
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
NO20053045L (no) Kinolyl-pyrrol-pyrazoler.
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
DK1202736T3 (da) Nikotin i terapeutisk angiogenese og vasculogenese
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
IS7983A (is) Notkun á palonsetron til að meðhöndla ógleði og uppköst eftir aðgerðir
DK0806948T3 (da) Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
WO2000066528A3 (en) Quinones for treatment of diseases
IS4820A (is) Aðferð til meðferðar uppsölu og truflana á miðtaugakerfi sem fela í sér notkun norkisapríðs með hreina (+) ljósvirkni
CY1106409T1 (el) Παραγωγα κινολινης
WO2001087849A3 (en) Modulators of tnf- alpha signaling
DE60025639D1 (de) Substituierte diazepan
WO2003084928A8 (en) Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
EA200400793A1 (ru) Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
WO2003092611A3 (en) Methods of inducing formation of functional and organized lymphatic vessels
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
MXPA04002492A (es) Uso novedoso de aminometil cromanos sustituidos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties